Exploratory secondary analysis of the phase III COLUMBUS trial (921 patients with BRAF V600E/K melanoma; up to 666 analysed): survival benefit of encorafenib plus binimetinib vs vemurafenib was greatest with higher TMB or tumour immune infiltration.
Secondary analysisn = 921
Dummer et al. Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma